Logo image of CERO

CERO THERAPEUTICS HOLDINGS I (CERO) Stock Fundamental Analysis

NASDAQ:CERO - Nasdaq - US71902K1051 - Common Stock - Currency: USD

1.79  -0.26 (-12.68%)

After market: 1.71 -0.08 (-4.47%)

Fundamental Rating

0

CERO gets a fundamental rating of 0 out of 10. The analysis compared the fundamentals against 572 industry peers in the Biotechnology industry. Both the profitability and financial health of CERO have multiple concerns. CERO does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CERO has reported negative net income.
In the past year CERO has reported a negative cash flow from operations.
CERO Yearly Net Income VS EBIT VS OCF VS FCFCERO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 -500K -1M -1.5M -2M -2.5M

1.2 Ratios

Looking at the Return On Assets, with a value of -142.62%, CERO is doing worse than 83.84% of the companies in the same industry.
Industry RankSector Rank
ROA -142.62%
ROE N/A
ROIC N/A
ROA(3y)-10.46%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CERO Yearly ROA, ROE, ROICCERO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 0 20 -20 40 -40

1.3 Margins

CERO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CERO Yearly Profit, Operating, Gross MarginsCERO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023

More info and screens

0

2. Health

2.1 Basic Checks

CERO has less shares outstanding than it did 1 year ago.
CERO has a worse debt/assets ratio than last year.
CERO Yearly Shares OutstandingCERO Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 5M 10M 15M 20M
CERO Yearly Total Debt VS Total AssetsCERO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 50M 100M 150M

2.2 Solvency

CERO has an Altman-Z score of -23.53. This is a bad value and indicates that CERO is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of CERO (-23.53) is worse than 88.28% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -23.53
ROIC/WACCN/A
WACCN/A
CERO Yearly LT Debt VS Equity VS FCFCERO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 0 50M 100M 150M

2.3 Liquidity

CERO has a Current Ratio of 0.39. This is a bad value and indicates that CERO is not financially healthy enough and could expect problems in meeting its short term obligations.
The Current ratio of CERO (0.39) is worse than 94.67% of its industry peers.
CERO has a Quick Ratio of 0.39. This is a bad value and indicates that CERO is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.39, CERO is not doing good in the industry: 94.32% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.39
Quick Ratio 0.39
CERO Yearly Current Assets VS Current LiabilitesCERO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 10M 20M 30M 40M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for CERO have decreased strongly by -8521.06% in the last year.
EPS 1Y (TTM)-8521.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-5631.18%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CERO Yearly Revenue VS EstimatesCERO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023
CERO Yearly EPS VS EstimatesCERO Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CERO. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CERO Price Earnings VS Forward Price EarningsCERO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CERO Per share dataCERO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -5 -10 -15 -20 -25

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CERO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CERO THERAPEUTICS HOLDINGS I

NASDAQ:CERO (2/21/2025, 8:07:15 PM)

After market: 1.71 -0.08 (-4.47%)

1.79

-0.26 (-12.68%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners4.47%
Inst Owner ChangeN/A
Ins Owners11.6%
Ins Owner Change0%
Market Cap5.42M
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short Ratio0.01
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-29.31
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-3.82
FCFYN/A
OCF(TTM)-3.82
OCFYN/A
SpS0
BVpS-1.22
TBVpS-1.22
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -142.62%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-10.46%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.39
Quick Ratio 0.39
Altman-Z -23.53
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-8521.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-5631.18%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-275.79%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-716.44%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-716.44%
OCF growth 3YN/A
OCF growth 5YN/A